Therapeutic agent for diabetes

A diabetes and disease technology, applied in pharmaceutical formulations, metabolic diseases, drug combinations, etc., can solve the problem of not knowing the treatment drugs for type II diabetes

Inactive Publication Date: 2014-09-24
TEIJIN PHARMA CO LTD +1
View PDF6 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is not known to be a therapeutic drug for type II diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for diabetes
  • Therapeutic agent for diabetes
  • Therapeutic agent for diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] [Example 1] Study on Effects on Insulin Resistance, Impaired Glucose Tolerance, and Instant Blood Glucose Levels in Mice Loaded with High Fat Meal

[0069] In order to study the effect of febuxostat (2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazole carboxylic acid) on insulin resistance, impaired glucose tolerance and blood glucose at any time, Febuxostat was administered to sick mice loaded with a high-fat diet and compared with the control group (vehicle group). In addition, in order to examine the relationship with the uric acid level in the blood, the uric acid level in the blood was measured.

[0070]

[0071] The 8-week-old male C57BL / 6J mice were loaded with a high-fat diet in which the proportion of calories from fat in the total calories (Fat Kcal%) was 60%. This leads to the onset of insulin resistance, impaired glucose tolerance and diabetes. For the febuxostat administration group, at the same time as the high-fat meal load was started, the tap water in...

Embodiment 2

[0101] [Example 2] Study on the Effect of Impaired Glucose Tolerance in Mice Loaded with High Fat Meal

[0102] To study the effect of febuxostat on impaired glucose tolerance, febuxostat was administered to sick mice loaded with a high-fat diet and compared with a control group (vehicle group).

[0103]

[0104]The 8-week-old male C57BL / 6J mice were loaded with a high-fat diet in which the proportion of calories from fat in the total calories (Fat Kcal%) was 60%. This leads to the onset of insulin resistance, impaired glucose tolerance and diabetes. For the febuxostat group, at the same time as the high-fat meal load started, the tap water with febuxostat dissolved in it was raised with the dose of 3 mg / kg / Day, and drinking water administration was carried out. Tap water for feeding.

[0105] At 12 weeks after the start of the high-fat meal load and febuxostat administration, a glucose load test was performed to evaluate impaired glucose tolerance. That is, 0.5 g / kg of g...

Embodiment 3

[0113] [Example 3] Administration of febuxostat preparations to patients with hyperuricemia

[0114] To study the effect of febuxostat preparations in patients with hyperuricemia whose blood uric acid value is above 7.0 mg / dL. Subjects were untreated diabetic patients aged 20 years or older, whose blood uric acid value was 7.0 mg / dL or higher, and who were not using urate-lowering drugs. Among them, patients with a presumed glomerular filtration rate of less than 30; patients with a history of hypersensitivity to febuxostat preparations; liver function (aspartate aminotransferase, and alanine aminotransferase) showed to be Patients who are more than 2 times the benchmark value of the drug implementing agency; patients with chronic liver disease, malignant tumor, active infection or inflammatory disease and other patients who are judged to be unsuitable by the attending doctor are excluded from the administration.

[0115] For this patient, febuxostat preparation 10 mg was adm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Description

technical field [0001] The present invention relates to a therapeutic or preventive drug for diseases caused by abnormal glucose metabolism, comprising a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. Background technique [0002] Abnormal glucose metabolism refers to a state in which an abnormality occurs in the metabolism of sugar, and diabetes is a representative disease caused by abnormal glucose metabolism. Known diabetes has type I and type II diabetes, type I diabetes is hyperglycemia caused by the absolute deficiency of insulin action, type II diabetes is hyperglycemia caused by absolute or relative insufficiency of insulin action , Blood sugar level 2 hours after sugar load, fasting blood sugar level (FBS), and hemoglobin A1c (HbA1c) rise are the main features of metabolic abnormalities, which cause unique complications after many years. [0003] In addition, in recent years, not only comp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/425A61P3/10
CPCA61K31/426A61P3/08A61P3/10
Inventor 久留一郎辻本俊亮白仓尚平光伸也
Owner TEIJIN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap